STAT+: Why this former ER doc thinks giving AI less information is sometimes better
STAT Health Tech · 10h ago
Novartis
Medicine & Biotech · covered by 19 outlets this week · tracked since 2026-10-27
Press: 1 mainstream 23 specialist 5 independent outlet-days
Background
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Novartis is one of the largest pharmaceutical companies in the world and was the eighth largest by revenue in 2024. Wikipedia ↗
Written by the Alivewire editors from the coverage below, 19h ago. Not medical advice; how the ratings work.
Coverage
PepGen soars on promising early data for muscular dystrophy drug
BioPharma Dive · 1d ago
FDA grants accelerated approval to asciminib for newly diagnosed chronic myeloid leukemia
FDA Drug Safety / Drugs feed · 1d ago
detranslation pending
Novartis: la FDA enquête sur des cas de tumeurs après une thérapie génique
Medinside · 1d ago
FDA approves dabrafenib with trametinib for pediatric patients with low-grade glioma with a BRAF V600E mutation
FDA Drug Safety / Drugs feed · 1d ago
FDA approves ribociclib with an aromatase inhibitor and ribociclib and letrozole co-pack for early high-risk breast cancer
FDA Drug Safety / Drugs feed · 1d ago
study
Vladimir Ivošev: 9 Tumors Reported in Patients Treated with Novartis’ Zolgensma SMA Gene Therapy
OncoDaily · 2d ago
Mohammad Al Nahedh Takes On Role of Oncology Medical Head at Novartis
OncoDaily · 2d ago
FDA investigates Novartis gene therapy link to tumours in children
EMJ Reviews · 2d ago
studyobservational
USFDA Probes Cancer Risk Linked to Novartis' Zolgensma, Nine Tumour Reports Recorded
Medical Dialogues · 2d ago
Novartis' pelacarsen fail raises questions for other drugs
Pharmaphorum · 2d ago
detranslation pending
„Aus Tierversuchen wissen wir, dass solche Gentherapien Krebs auslösen können“
Welt Gesundheit · 3d ago
Pelacarsen does not reduce CV events in patients with high Lp(a)
Healio · 4d ago
study
STAT+: Failure of Novartis Lp(a) drug raises questions about cardiovascular strategy
STAT News · 4d ago
n=177
FDA approves lutetium Lu 177 dotatate for pediatric patients 12 years and older with GEP-NETS
FDA Drug Safety / Drugs feed · 5d ago
Gene Therapy Under Scrutiny After Nine Tumor Reports
MedPage Today · 5d ago
Novartis Confirms Nine Cases of Tumors in Children Treated with Gene Therapy Zolgensma
GEN Genetic Engineering News · 5d ago
studyobservational
Novartis reveals cancer cases possibly linked to gene therapy Zolgensma
BioPharma Dive · 5d ago
observational
STAT+: Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
STAT Biotech · 6d ago
Novartis exits a BioArctic deal worth up to $802m
Longevity.Technology · 6d ago
Kisqali OS gain came sooner than expected in early breast cancer: oncologist
Korea Biomedical Review · 6d ago
Korea approves Novartis' Vanrafia, first selective ETA blocker for IgA nephropathy
Korea Biomedical Review · 7d ago
ittranslation pending
Catalyst: un progetto Novartis per rafforzare la capacità organizzativa dei centri
Quotidiano Sanità · 7d ago
Novartis ends BioArctic deal: “Nothing to do with BrainTransporter”
Life Science Sweden · 8d ago
Earnings roundup: Lilly’s unwavering momentum, Novartis’ rebound and GSK’s waiting game
BioPharma Dive · 12d ago
Lilly shuffles business structure; Novartis writes off part of Avidity deal
BioPharma Dive · 14d ago
study
Patients Deaths and Data Shortfall Spell the End for Cell Therapy Biotech Artiva
MedCity News · 15d ago
Artiva to quit autoimmune cell therapy work, cut staff after patient deaths
BioPharma Dive · 15d ago
Novartis takes $1.9bn hit from Avidity takeover in Q3
Pharmaphorum · 15d ago
STAT+: Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
STAT Biotech · 19d ago
The case for regeneration over slowing decline
Longevity.Technology · 34d ago